Author's response to reviews

Title: The role of a new CD44 variant in increasing invasion capability to human breast cancer cell line MCF-7

Authors:

   Xin-Jian Fang (fangruirui@yeah.net)
   Wei-Mei Jiang (jiangweimei@126.com)
   Chun-Xia Hu (huchunxia01@163.com)
   Hua Jiang (lygfxj@126.com)

Version: 2 Date: 17 December 2009

Author's response to reviews:

Dear sir, madam, or Other:

I would like to submit the manuscript, “The role of a new CD44 variant in increasing invasion capability to human breast cancer cell line MCF-7”, for consideration for possible publication in the your journal.

CD44 has been thought to be a type I transmembrane glycoprotein receptor that implicate in cell adhesion, motility, and metastases which are important in cancer progression, hematopoietic development, wound healing, and apoptosis. In this paper, a new CD44 isoforms was found in multidrug resistant carcinoma cells(MCF-7/Adr, LoVo/Adr, HL-60/Adr and K562/Adr) and inserted into the eukaryotic expression vector pcDNA3.1(pcDNA3.1-CD44v18). Meanwhile, we investigated the production of matrix metalloproteinase (MMP) by HA stimulation in a human cancer cell line, MCF-7, that was transfected into pcDNA3.1-CD44v18 by Lipofectamine. we show that treatment of MCF-7/CD44v18 cells with HA strongly activated MMP-2 and MMP-9 secretion. Taken together, we found that MAPK signaling pathway plays a key role in the HA-dependent secretion of MMP-2 and MMP-9 and, hence, in the invasiveness of MCF-7/CD44v18 cells.

On behalf of my co-authors, I am submitting the enclosed material for possible publication in (name of journal). It has not been submitted for publication nor has it been published in whole or in part elsewhere. I attest to the fact that all authors listed on the title page have read the manuscript, attest to the validity and legitimacy of the data and its interpretation, and agree to its submission to (name of journal).

We believe the paper may be of particular interest to the readers of your journal.
Correspondence and phone calls about the paper should be directed to Jiang Hua at the following address#phone and fax number#and e-mail address#

Institute: Department of Medical Oncology

Address: No. 41, Hailian east Road, Lianyungang, Jiangsu 222000, The People's Republic of China

Tel:051885807277

Fax: :051885807277

E-mail#lygfxj@126.com

Thanks very much for your attention to our paper#

Sincerely yours#

Jiang Hua